Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of GH35 Tablets in Patients Harboring With G12C Mutation in Advanced Solid Tumors

NCT05010694 is registered in ClinicalTrials.gov with Suzhou Genhouse Bio Co., Ltd. as lead sponsor.

NCT NCT05010694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05010694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of GH35 Tablets in Patients Harboring With G12C Mutation in Advanced Solid Tumors
Lead sponsor
Suzhou Genhouse Bio Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
September 27, 2021
Completion date
December 12, 2025
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors harboring with g12c mutation